A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

People considering weight-loss ... Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more effective for weight loss.

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have ... and sustained weight loss," Wegovy is "the ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...

Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.